The current stock price of INMD is 14.48 USD. In the past month the price increased by 4.1%. In the past year, price decreased by -15.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.59B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.41 | 196.60B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.51 | 137.79B | ||
| SYK | STRYKER CORP | 26.7 | 134.49B | ||
| BDX | BECTON DICKINSON AND CO | 13.62 | 56.05B | ||
| IDXX | IDEXX LABORATORIES INC | 54.97 | 55.35B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.2 | 49.51B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.92 | 37.47B | ||
| RMD | RESMED INC | 24.98 | 36.10B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 63.18 | 20.31B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.24 | 18.02B |
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 599
Phone: 97249097470
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
The current stock price of INMD is 14.48 USD. The price increased by 1.05% in the last trading session.
INMD does not pay a dividend.
INMD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
14 analysts have analysed INMD and the average price target is 17.14 USD. This implies a price increase of 18.34% is expected in the next year compared to the current price of 14.48.
INMODE LTD (INMD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
INMODE LTD (INMD) will report earnings on 2026-02-02, before the market open.
ChartMill assigns a technical rating of 1 / 10 to INMD. When comparing the yearly performance of all stocks, INMD is a bad performer in the overall market: 76.15% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to INMD. INMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS decreased by -23.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.1% | ||
| ROA | 20.39% | ||
| ROE | 22.93% | ||
| Debt/Equity | 0 |
14 analysts have analysed INMD and the average price target is 17.14 USD. This implies a price increase of 18.34% is expected in the next year compared to the current price of 14.48.
For the next year, analysts expect an EPS growth of -9.69% and a revenue growth -8.35% for INMD